secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001437749-26-013195
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart appoints Dr. James Breitmeyer to board of directors
----------------------------------------------------------

- Dr. James Breitmeyer appointed to Vaxart Board effective April 23, 2026.
- Brings over 35 years biopharma experience; led programs yielding 8 FDA product approvals.
- Currently CEO and director of Altay Therapeutics; formerly President & CEO of Oncternal Therapeutics (2016-2025).
- Prior roles include President of Bavarian Nordic (cancer/infectious disease vaccines) and senior clinical leadership at Eli Lilly and Cadence.
- Will receive standard non-employee director cash and equity compensation under Vaxart's program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774926013195/0001437749-26-013195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774926013195/vxrt20260423_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer